Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Suncare Research Laboratories

Winston-Salem, North Carolina, 27106, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Normal healthy volunteers
18 years of age or older

Exclusion criteria

Less than 18 years of age

Treatment and study plan

Atralin (tretinoin) Gel, 0.05%

Drug

Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.

Primary outcomes

UV induced skin sensitization

Time frame: 4 days

Sponsors and collaborators

Lead sponsor

Coria Laboratories, Ltd.

Industry

Registry information

Official study title

Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Jan 29, 2008
Registry last updated: Mar 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed